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Cardiovascular disease (CVD) is the leading cause of death worldwide, with an age-standardized mortality 
rate of 278 per 100 000 population per year.1 The term CVD 
encompasses a range of conditions, of which coronary artery 
disease (CAD) and stroke are the most common, with a global 
prevalence of 154 and 80 million people, respectively,2 and 
together accounting for 85% of CVD deaths.1 Therefore, they 
are a significant public health concern.1,2 Platelets are involved 
in thrombosis, with the 150 000 to 450 000 platelets found per 
milliliter of blood in healthy individuals forming the basis of 
blood clots.3 Furthermore, platelet aggregation is implicated 
in CVD risk, with antiplatelet therapy a core component of 
secondary prevention, as well as primary prevention in high-
risk individuals.4 Despite the key role of platelets in the path-
ogenesis of acute CVD events, there is conflicting evidence 
from observational studies on the association between platelet 
count and risk of CVD.5–10 Greater understanding of this 
relationship would offer further insight into the pathophysi-
ology of these conditions, which may in turn guide research 
efforts toward disease prevention.
The Mendelian randomization (MR) approach uses ge-
netic variants associated with an exposure of interest as 
instruments to investigate the effect of varying that exposure 
on an outcome (Figure 1).11,12 Based on the assumption that 
the genetic variants used as instruments only associate with 
the outcome through the exposure, MR is devoid of bias from 
confounding environmental factors and reverse causation in 
the way that observational studies can be.11 The MR study de-
sign is, therefore, comparable to the random allocation of an 
intervention, or exposure, in a randomized controlled trial.11 
Two-sample MR uses genetic associations with the exposure 
and outcome, respectively, from 2 separate population groups 
on the assumption that these populations are homogeneous,13 
and can increase the potential scope for the application of 
Received on: August 22, 2018; final version accepted on: September 24, 2018.
From the Department of Biostatistics and Epidemiology (D.G., G.M.), and MRC-PHE Centre for Environment (I.T.), School of Public Health, Imperial 
College London, United Kingdom; Institute for Stroke and Dementia Research, University Hospital of Ludwig-Maximilians-University (LMU), Munich, 
Germany (M.K.G.); Department of Hygiene and Epidemiology, University of Ioannina Medical School, Greece (I.T.); and Centre for Haematology, 
Imperial College London, United Kingdom (M.L.).
The online-only Data Supplement is available with this article at https://www.ahajournals.org/doi/suppl/10.1161/ATVBAHA.118.311804.
Correspondence to Dipender Gill, MD, Department of Biostatistics and Epidemiology, School of Public Health, Medical School Bldg, St Mary’s 
Hospital, Norfolk Pl, Imperial College London, United Kingdom, W2 1PG. Email dipender.gill@imperial.ac.uk
© 2018 The Authors. Arteriosclerosis, Thrombosis, and Vascular Biology is published on behalf of the American Heart Association, Inc., by Wolters 
Kluwer Health, Inc. This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution, and 
reproduction in any medium, provided that the original work is properly cited.
Objective—Cardiovascular disease, including coronary artery disease (CAD) and ischemic stroke, is the leading cause of 
death worldwide. This Mendelian randomization study uses genetic variants as instruments to investigate whether there 
is a causal effect of genetically determined platelet count on CAD and ischemic stroke risk.
Approach and Results—A genome-wide association study of 166 066 subjects was used to identify instruments and genetic 
association estimates for platelet count. Genetic association estimates for CAD and ischemic stroke were obtained from 
genome-wide association studies, including 60 801 CAD cases and 123 504 controls, and 60 341 ischemic stroke cases and 
454 450 controls, respectively. The inverse-variance weighted meta-analysis of ratio method Mendelian randomization 
estimates was the main method used to obtain estimates for the causal effect of genetically determined platelet count 
on risk of cardiovascular outcomes. We found no significant Mendelian randomization effect of genetically determined 
platelet count on risk of CAD (odds ratio of CAD per SD unit increase in genetically determined platelet count, 1.01; 95% 
CI, 0.98–1.04; P=0.60). However, higher genetically determined platelet count was causally associated with an increased 
risk of ischemic stroke (odds ratio, 1.07; 95% CI, 1.04–1.11; P<1×10−5), including all major ischemic stroke subtypes. 
Similar results were obtained in sensitivity analyses more robust to the inclusion of pleiotropic genetic variants.
Conclusions—This Mendelian randomization study found evidence that higher genetically determined platelet count is 
causally associated with higher risk of ischemic stroke.
Visual Overview—An online visual overview is available for this article.  (Arterioscler Thromb Vasc Biol. 2018;38:2862-
2869. DOI: 10.1161/ATVBAHA.118.311804.)
Key Words: blood platelet ◼ cardiovascular diseases ◼ coronary artery disease ◼ myocardial infarction ◼ stroke
Genetically Determined Platelet Count and Risk  
of Cardiovascular Disease
Mendelian Randomization Study
Dipender Gill, Grace Monori, Marios K. Georgakis, Ioanna Tzoulaki, Mike Laffan
Arterioscler Thromb Vasc Biol is available at https://www.ahajournals.org/journal/atvb DOI: 10.1161/ATVBAHA.118.311804
https://www.ahajournals.org/journal/atvb
Gill et al  Platelet Count and Risk of Cardiovascular Disease  2863
the MR methodology.14 Genetic variants that may be used as 
instruments in MR analysis include single-nucleotide poly-
morphisms (SNPs) that are selected based on their association 
with the exposure of interest,15 which in our present study is 
platelet count.
In this study, we used the MR technique to investigate for 
a causal effect of genetically determined platelet count on risk 
of CAD and ischemic stroke. Furthermore, we investigated 
the causal effect of genetically determined platelet count on 
risk of myocardial infarction (MI) and ischemic stroke sub-
types (large-artery atherosclerotic stroke, small vessel stroke, 
and cardioembolic stroke) in secondary analyses. The primary 
and secondary outcomes studied are depicted in Figure 1.
Materials and Methods
All the data used for this work are available within the article and its 
online-only Data Supplement.
SNP-Platelet Count Genetic Association Estimates
Genetic association estimates for platelet count were taken from a 
genome-wide association study meta-analysis performed using the 
INTERVAL and UK Biobank studies (including the UK Biobank 
Lung Exome Variant Evaluation study), which included 166 066 sub-
jects of European ancestry.16 Platelet count was measured in a total 
of 83 565 (45 372 women; 38 193 men) subjects in the UK Biobank 
study, 43 562 subjects (21 702 women; 21 860 men) in the UK Biobank 
Lung Exome Variant Evaluation study, and 38 939 (19 661 females; 
19 278 males) in the INTERVAL study.16 Adjustments were made for 
age, sex, body mass index, alcohol consumption, and smoking status. 
The SD of platelet count was 55.3×10−9/L (55.3/nL) in women and 
51.1×10−9/L (51.1/nL) in males for the UK Biobank cohort.16 This 
meta-analysis found 219 SNPs with minor allele frequency >0.01 that 
were related to platelet count at genome-wide significance (P value 
<5×10−8) that had available rsID codes (Table I in the online-only 
Data Supplement).
The strength of the instruments was assessed using the F statistic, 
calculated using the equation F=R2(n−2)/(1−R2), where R2 is the pro-
portion of the variability in genetically determined platelet count 
accounted for by the SNP and n is the sample size.17 An F statistic 
of >10 indicates a relatively low risk of weak instrument bias in MR 
analyses.17
Association Estimates for SNP-CVD Relationships
The SNP-cardiovascular risk association estimates were obtained 
from 2 separate genome-wide association study meta-analyses.18,19 
For CAD and MI, the Coronary Artery Disease Genome-Wide 
Replication and Meta-Analysis plus Coronary Artery Disease 
Genetics Consortium’s 1000 genomes-based meta-analysis included 
data from individuals of European, Hispanic, African American, and 
South and East Asian ancestry, for 60 801 cases of CAD, of which MI 
made up ≈70% of cases, and 123 504 control subjects.18 Case subjects 
were defined as those with a documented diagnosis of CAD, such 
as acute coronary syndrome (including MI), chronic stable angina, 
or >50% stenosis of at least 1 coronary vessel, as well as those who 
had undergone percutaneous coronary revascularization or coronary 
artery bypass grafting.18
The MEGASTROKE (Multiancestry Genome-wide Association 
Study of Stroke) consortium amalgamated data from 29 studies, in-
cluding data from individuals of European, Latin American, African 
and East, South and Mixed Asian descent, with 60 341 cases of is-
chemic stroke, comprising of 9006 cases of cardioembolic stroke, 
6688 cases of large-artery atherosclerotic stroke, 11 710 cases of 
small vessel stroke, and 454 450 control subjects.19 Cases of stroke 
were diagnosed based on the World Health Organization diagnostic 
criteria of sudden onset of neurological changes lasting at least 24 
hours of presumed vascular origin, with subtypes defined using the 
TOAST criteria.19
Mendelian Randomization Estimates
The association between genetically determined platelet count and 
CVD risk attributable to each SNP was estimated using the Wald 
method, which calculates the ratio between the SNP-CVD risk and 
SNP-platelet count estimates.14 The Delta method was used to cal-
culate the SE (second order weights), as this approach acknowledges 
uncertainty in the genetic association estimates.14 The fixed-effect 
inverse-variance weighted (IVW) meta-analysis method was used 
to combine MR estimates for the individual SNPs in the main anal-
ysis.14 The exposure examined was genetically determined platelet 
count, and the primary outcomes were CAD risk and ischemic stroke 
risk. Secondary outcomes studied were MI risk, and risk of ischemic 
stroke subtypes, including large-artery atherosclerotic stroke, cardio-
embolic stroke, and small vessel stroke. For the 2 primary outcomes, 
a statistical significance threshold of P<0.025 was used after apply-
ing a stringent Bonferroni correction for multiple testing. For sec-
ondary outcomes, a threshold of P<0.05 was used, as these analyses 
were only performed to further replicate the findings of the primary 
analyses.
Investigation of Pleiotropy
Pleiotropy in this context refers to multiple effects of a genetic var-
iant. When SNPs used as instruments in MR analysis are pleiotropic, 
they may affect the outcome independently of the exposure under 
consideration.11 For example, SNPs used as instruments for platelet 
count may affect CVD risk through effects independent of platelet 
count. This can lead to confounding and bias of MR estimates.11 
Therefore, it is important to investigate for pleiotropy when conduct-
ing an MR analysis. To do this, we used several approaches. First, 
we measured the heterogeneity in MR estimates produced by differ-
ent SNPs in the fixed-effect IVW meta-analysis using the I2 index 
(I2
MR
) and the Cochran Q statistic, based on the principle that if there 
Nonstandard Abbreviations and Acronyms
CAD  coronary artery disease
CVD  cardiovascular disease
IVW  inverse-variance weighted
MEGASTROKE  Multiancestry Genome-wide Association Study of 
Stroke
MI  myocardial infarction
MR  Mendelian randomization
OR  odds ratio
PRESSO  pleiotropy residual sum and outlier
SNP  single-nucleotide polymorphism
Figure 1. Schematic depiction of our study design, detailing the primary 
and secondary outcome variables investigated. The dashed arrows repre-
sent the associations used in a Mendelian randomization study. The solid 
arrow represents the Mendelian randomization (MR) causal effect inferred 
in the results of a Mendelian randomization study. CAD indicates coronary 
artery disease; CE, cardioembolic; CVD, cardiovascular disease; LAS, 
large artery stroke; MI, myocardial infarction; and SVS, small vessel stroke.
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were no pleiotropic effects occurring then estimates between differ-
ent SNPs should vary only by chance and, therefore, heterogeneity 
would be low.20 We defined I2
MR
>25% and Cochran Q-derived P value 
<0.05 as indicative of excessive heterogeneity and thus pleiotropy.
Furthermore, secondary phenotypes associated with all the instru-
ment SNPs studied were also searched for using PhenoScanner (www.
phenoscanner.medschl.cam.ac.uk/phenoscanner).21 PhenoScanner 
is an online database that includes data from publicly available 
genome-wide association studies with over 10 million SNPs. The 
secondary SNP associations reaching genome-wide significance (P 
value <5×10−8) with linkage disequilibrium r2>0.8 were considered as 
potentially exerting pleiotropy, and sensitivity MR analyses using the 
fixed-effect IVW method that excluded these SNPs were performed. 
The details of the 39 SNPs excluded for their potentially pleiotropic 
effects are shown in Table II in the online-only Data Supplement.
MR-Egger was used as a further statistical sensitivity analysis. 
This is based on the Egger test used to investigate small-study bias in 
meta-analyses.22 It assumes that any direct effects of the SNPs on the 
outcome (ie, pleiotropic effects) are independent of their association 
with platelet count (instrument strength independent of direct effect 
assumption).22 MR-Egger offers a test for pleiotropy that is biasing 
the MR estimate and also produces MR estimates that are adjusted 
for this. If the value for the MR-Egger intercept is 0 (tested here 
using a P-value threshold of ≥0.05), then this indicates that there is 
no evidence of directional pleiotropy being present. Heterogeneity 
between the individual SNP-platelet count estimates (quanti-
fied using an I2 index, I2
GX
) was used to calculate potential bias in 
MR-Egger introduced because of measurement error, with an I2
GX
 
of >95% considered low risk.23 We also calculated the Rucker’s Qʹ 
statistic that measures heterogeneity in the MR-Egger analysis, and 
tested whether it differed significantly from the Cochran’s Q result, 
as a significantly lower Qʹ statistic is indicative of the MR-Egger 
approach providing a model with better fit for examining the partic-
ular association.24
In addition, the MR pleiotropy residual sum and outlier 
(MR-PRESSO) test was used in our sensitivity analyses to test for 
pleiotropy.25 MR-PRESSO detects pleiotropic effects of the SNPs by 
comparing the residuals for each SNP in the zero-intercept regression 
line of the SNP-outcome estimates by the SNP-exposure estimates 
with that expected in the absence of pleiotropic effects.25 MR-PRESSO 
analysis is then again performed after removing the outliers detected, 
hence correcting for pleiotropic effects.25 It is based on the assumption 
that at least 50% of the SNPs are valid instruments.25
The weighted median estimator MR statistical sensitivity test 
does not rely on the instrument strength is independent of direct effect 
assumption, and is valid when <50% of the information for the anal-
ysis comes from invalid instruments.26 Therefore, we also performed 
weighted median MR analysis, which takes the median estimate from 
the SNP-platelet count association estimates ranked in order of mag-
nitude and weighted for their precision, with a parametric bootstrap 
method used to calculate the 95% CIs.22,26
Finally, we also performed weighted mode-based estimator MR 
analysis, which generates an overall MR result from the greatest 
number of SNPs that produce similar MR estimates, and is reliable 
when this group of SNPs is valid.27 This approach is based on the 
rationale that the largest number of SNPs producing similar MR esti-
mates may be less likely to be biased because of possible pleiotropic 
effects.27 P value thresholds of P<0.05 were used in all sensitivity 
analyses to ascertain statistical significance when replicating the find-
ings of the main analysis.
The data from the meta-analyses used in this study are publicly 
available, and ethical approval was obtained in the original constit-
uent studies.16,18,19 Data were analyzed using the statistical program R 
(version 3.4.3; The R Foundation for Statistical Computing).
Results
SNP-Platelet Count and SNP-CVD Associations
The SNP-platelet count associations for the instrument SNPs 
identified in the INTERVAL and UK Biobank studies are 
shown in Table I in the online-only Data Supplement. The 
instruments had F statistics ranging from 37 to 1526 and were, 
therefore, at low risk of weak instrument bias (Table I in the 
online-only Data Supplement).17
Genetically Determined Platelet Count-
CVD Risk MR Estimates
IVW-MR Analysis
The IVW-MR estimates for individual SNPs are reported in 
Tables III through VIII in the online-only Data Supplement 
for CAD, MI, ischemic stroke, cardioembolic stroke, large-
artery atherosclerotic stroke, and small vessel stroke, re-
spectively. All MR estimates are reported as odds ratio (OR) 
of CVD outcome per SD unit increase in genetically deter-
mined platelet count. The main IVW-MR analysis did not 
find higher genetically determined platelet count to be as-
sociated with risk of CAD (OR, 1.01; 95% CI, 0.98–1.04; 
P=0.60) or MI (OR, 1.03; 95% CI, 0.99–1.07; P=0.12). 
However, higher genetically determined platelet count was 
causally associated with a detrimental effect on ischemic 
stroke risk (OR, 1.07; 95% CI, 1.04–1.11; P<1×10−5). For 
the ischemic stroke subtypes, higher genetically determined 
platelet count was associated with an increased risk of car-
dioembolic stroke (OR, 1.12; 95% CI, 1.05–1.19; P=5×10−4), 
large-artery atherosclerotic stroke (OR, 1.09; 95% CI, 1.01–
1.17; P=0.03), and small vessel stroke (OR, 1.08; 95% CI, 
1.01–1.15 P=0.02).
There was evidence of heterogeneity between individual 
SNP-MR estimates in all analyses performed using the IVW 
approach (Table X in the online-only Data Supplement), 
suggestive of potential pleiotropy. Funnel and radial plots 
to visually evaluate this pleiotropy are provided in Figures I 
through VI in the online-only Data Supplement. To investigate 
whether pleiotropic effects were responsible for our results, 
IVW-MR analysis was conducted after excluding SNPs with 
potentially pleiotropic effects, as identified by searching the 
PhenoScanner database21 and detailed in Table II in the online-
only Data Supplement. After this, we found that there was still 
no association of genetically determined platelet count with 
risk of CAD (OR, 1.01; 95% CI, 0.95–1.06; P=0.85) or risk 
of MI (OR, 1.05; 95% CI, 1.00–1.11; P=0.07). However, the 
association between genetically determined platelet count 
and risk of ischemic stroke remained significant (OR, 1.05; 
95% CI, 1.01–1.10; P=0.02). Although the MR estimates for 
risk of cardioembolic stroke (OR, 1.09; 95% CI, 1.00–1.19; 
P=0.05) and large-artery atherosclerotic stroke (OR, 1.06; 
95% CI, 0.96–1.18; P=0.25) remained similar to the main 
analysis, they were no longer statistically significant, likely 
because of wider CIs. The relationship between genetically 
determined platelet count and increased risk of small vessel 
stroke remained statistically significant (OR, 1.09; 95% CI, 
1.00–1.18; P=0.04).
MR-Egger
MR-Egger found that a higher genetically determined platelet 
count was not associated with an increased risk of CAD (OR, 
1.11; 95% CI, 0.99–1.24; P=0.08) or MI (OR, 1.11; 95% CI, 
0.99–1.25; P=0.08). As with the main IVW analysis, higher 
genetically determined platelet count was associated with an 
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increased risk of ischemic stroke (OR, 1.13; 95% CI, 1.03–
1.23; P=0.01). For the ischemic stroke subtypes, MR-Egger 
revealed that higher genetically determined platelet count 
was associated with an increased risk of cardioembolic 
stroke (OR, 1.19; 95% CI, 1.03–1.39; P=0.02), but not large-
artery atherosclerotic stroke (OR, 1.18; 95% CI, 0.98–1.43; 
P=0.08), or small vessel stroke (OR, 1.10; 95% CI, 0.93–1.29; 
P=0.26). While the effect estimates remained similar to the 
main IVW-MR analysis, any loss of statistical significance 
was attributable to wider CIs. The MR-Egger intercepts, 
which measure pleiotropy that may bias the main IVW-MR 
estimates, did not reach statistical significance for any of the 
CVD subtypes (CAD: P=0.05; MI: P=0.13; ischemic stroke: 
P=0.21; cardioembolic stroke: P=0.36; large-artery athero-
sclerotic stroke: P=0.33; small vessel stroke: P=0.84). The 
I2 index (I2
GX
) was calculated to test for heterogeneity be-
tween the individual SNP-platelet count estimates and was 
99%, suggesting therefore there was a low risk of bias with 
MR-Egger because of measurement error.23 Similarly to the 
IVW analyses, there was evidence of heterogeneity in all 
MR-Egger analyses, as indicated by the Rucker’s Qʹ statis-
tics (Table X in the online-only Data Supplement). However, 
only for CAD and MI was the Rucker’s Qʹ significantly lower 
than the Cochran’s Q to indicate a better fit for the MR-Egger 
approach than the IVW method.
Mendelian Randomization Pleiotropy 
Residual Sum and Outlier
Genetically determined platelet count was not associated with 
an increased risk of CAD in the main MR-PRESSO anal-
ysis (OR risk per SD unit increase in genetically determined 
platelet count: 1.00; 95% CI, 0.95–1.06; P=0.92) or outlier-
corrected analysis (OR, 1.01; 95% CI, 0.96–1.05; P=0.78). 
Nor was genetically determined platelet count associated 
with risk of MI in the main MR-PRESSO analysis (OR, 1.03; 
95% CI, 0.97–1.09; P=0.36) or the outlier-corrected analysis 
(OR, 1.02; 95% CI, 0.98–1.07; P=0.33). In concordance with 
the main IVW-MR analysis, genetically determined platelet 
count was associated with an increased risk of ischemic stroke 
in both the main MR-PRESSO analysis (OR, 1.07; 95% CI, 
1.03–1.12; P=7×10-4) and the outlier-corrected analysis (OR, 
1.05; 95% CI, 1.02–1.09; P=5×10−3). Of the ischemic stroke 
subtypes, genetically determined platelet count was associ-
ated with an increased risk of cardioembolic stroke in the 
main MR-PRESSO analysis (OR, 1.12; 95% CI, 1.04–1.20; 
P=2×10−3). No outliers were detected for cardioembolic 
stroke. Genetically determined platelet count was not asso-
ciated with an increased risk of large-artery atherosclerotic 
stroke in the main MR-PRESSO analysis (OR, 1.09; 95% 
CI, 1.00–1.19; P=0.06) or the outlier-corrected analysis (OR, 
1.06; 95% CI, 0.97–1.16; P=0.19). Genetically determined 
platelet count was associated with an increased risk of small 
vessel stroke in the main MR-PRESSO analysis (OR, 1.08; 
95% CI, 1.00–1.17; P=0.04) but not the outlier-corrected 
analysis (OR, 1.06; 95% CI, 0.99–1.14; P=0.12). The SNPs 
excluded in each outlier-corrected MR-PRESSO analysis are 
presented in Table IX in the online-only Data Supplement. 
The distortion P value was 0.92 for CAD, 0.88 for MI, 0.12 
for ischemic stroke, 0.32 for large-artery atherosclerotic 
stroke, and 0.39 for small vessel stroke, suggesting that any 
outlier SNPs were unlikely to be significantly biasing the 
estimates.
Weighted Median MR
Weighted median MR analyses showed that genetically de-
termined platelet count was not associated with risk of CAD 
(OR, 1.04; 95% CI, 0.97–1.10; P=0.27), or MI (OR, 1.02; 
95% CI, 0.95–1.09; P=0.54). However, higher genetically de-
termined platelet count was associated with an increased risk 
of ischemic stroke (OR, 1.08; 95% CI, 1.03–1.14; P=3×10−3). 
For the ischemic stroke subtypes, higher genetically deter-
mined platelet count was associated with an increased risk of 
cardioembolic stroke (OR, 1.16; 95% CI, 1.03–1.30; P=0.01), 
but not risk of large-artery atherosclerotic stroke (OR, 1.07; 
95% CI, 0.94–1.23; P=0.30), or small vessel stroke (OR, 1.09; 
95% CI, 0.98–1.21; P=0.13). As with the other sensitivity 
analyses, although the estimate remained similar, the size of 
the CIs increased.
Weighted Mode-Based Estimator MR
Finally, the weighted-mode based MR also produced sim-
ilar MR estimates to the main analysis, but with wider 95% 
CIs. There was no evidence of an MR effect of genetically 
determined platelet count on risk of CAD (OR, 0.99; 95% 
CI, 0.91–1.08; P=0.85) or MI (OR, 1.01; 95% CI, 0.91–1.11; 
P=0.91). However, for ischemic stroke (OR, 1.07; 95% CI, 
1.00–1.15; P=0.06) and its subtypes (cardioembolic stroke: 
OR, 1.18; 95% CI, 0.99–1.40; P=0.07; large-artery athero-
sclerotic stroke: OR, 1.04; 95% CI, 0.87–1.25; P=0.65; and 
small vessel stroke: OR, 1.14; 95% CI, 0.98–1.33; P=0.09), 
there was a suggestion of increased risk with higher geneti-
cally determined platelet count, but this did not reach statis-
tical significance.
Summary results of the MR estimates on CVD risk de-
rived from the main IVW, IVW excluding potentially plei-
otropic SNPs, MR-Egger, MR-PRESSO, outlier-corrected 
MR-PRESSO, weighted median, and weighted mode-based 
estimator methods are presented in Figure 2 for CAD and MI, 
and Figure 3 for ischemic stroke, cardioembolic stroke, large-
artery atherosclerotic stroke, and small vessel stroke.
Discussion
This study investigated the effect of genetically determined 
platelet count on risk of CAD and ischemic stroke using an 
MR approach. We report evidence that a higher genetically 
determined platelet count was associated with increased risk 
of ischemic stroke, but not CAD nor MI. Both MI and is-
chemic stroke typically result from occlusion to blood flow 
by a thrombus,28,29 and therefore platelets have a critical role 
in the pathogenesis of both diseases.28 Given this common-
ality, it is somewhat unexpected that we find that evidence 
for higher genetically determined platelet count being asso-
ciated with an increased risk of ischemic stroke, but not CAD 
or MI. Studies investigating the composition of thrombi in 
acute MI found that platelets accounted for 17%,30 while this 
was between 30% and 50% for ischemic stroke.31 The greater 
relative contribution of platelets to the thrombi in ischemic 
stroke compared with MI may go some way to explaining the 
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findings of our study, with a higher platelet count having more 
effect on diseases where platelets make up a larger proportion 
of the thrombus. Additionally, some of the discrepancy in the 
findings between CAD and ischemic stroke may relate to the 
caliber of the respective vessels, with coronary arteries gen-
erally having a larger diameter than cerebral arteries,32,33 with 
potential implications on the pathophysiology of thrombus 
formation. Furthermore, it may be that our investigation for 
the association between platelet count and risk of CAD or 
MI-lacked sufficient statistical power. Indeed, for the analyses 
of MI, there was some suggestion of increased risk with higher 
platelet count in all MR analyses (Figure 2), although this did 
not reach statistical significance. Furthermore, the CAD-MR 
analyses may have been affected by pleiotropic SNPs, with 
the MR-Egger test for this just missing statistical significance 
(P=0.05), and the MR-Egger estimate that adjusted for this 
approaching statistical significance (OR, 1.11; 95% CI, 0.99–
1.24; P=0.08). Comparisons of clot structure between stroke 
subtypes suggest that cardioembolic strokes have greater pro-
portions of platelets34 and fibrin35 than large-artery strokes, 
consistent with the findings reported here. It is therefore sur-
prising that antiplatelet therapy is of limited benefit for stroke 
prevention in the context of atrial fibrillation, although the 
benefit from anticoagulation may be explained by the high fi-
brin content.
Findings in Context
The effect of platelet traits on CAD risk has previously been 
investigated using an MR framework, and in keeping with our 
current findings, no effect of genetically determined platelet 
count was identified.16 Our study goes further to also explore 
ischemic stroke as an outcome, for which we do find MR evi-
dence of an effect of genetically determined platelet count on 
overall risk of ischemic stroke, as well as its subtypes.
While some observational work has found an associa-
tion between a higher platelet count and risk of CAD,36 and 
a higher platelet count in cases of MI or unstable angina 
compared with controls,8 others studies have reported no 
significant difference in platelet count between cases and 
controls for CAD or MI.37–39 Furthermore, a cohort study of 
hemodialysis patients found that higher platelet count was as-
sociated with a lower risk of CAD,39 and although it is unclear 
whether this is generalizable to healthy individuals, other 
studies have also reported a higher platelet count to be asso-
ciated with lower risk of MI.9,40 Of note, case-control studies 
may be affected by the measurement of platelet count after the 
incident case of CAD, which may limit interpretation because 
of possible reverse causation. For example, Yaghoubi et al40 
measured platelet count up to 24 hours after symptom onset in 
MI or unstable angina, while Panwar et al8 measured platelet 
count up to 24 hours after admission with an MI or unstable 
angina event.
Looking at ischemic stroke, a case-control study based 
in Turkey found that platelet count was significantly higher 
in cases compared with controls.7 These results were rep-
licated in case-control studies in Hungary41 and in China.6 
However, another case-control study set in China reported 
no significant difference between platelet count in cases 
and controls.5 Furthermore, the Cardiovascular Health 
Study, including a cohort of 5766 individuals, of whom 
807 developed ischemic strokes, found no relationship be-
tween platelet count and risk of ischemic stroke after 12 
to 15 years of follow-up.9 These results were supported by 
the European Prospective Investigation into Cancer and 
Nutrition-Netherlands cohort study (average follow-up 11.4 
years), which also reported no relationship between platelet 
count and risk of stroke.36
Other cohort studies have looked at overall CVD risk, and 
a cohort study in Denmark with a 3.5 year follow-up period 
found that platelet count was associated with increased risk 
of CVD.10 In contrast to the case-control studies, the cohort 
studies carry the benefit of measuring platelet count before 
ischemic stroke incidence, avoiding spurious associations 
from reverse causation. A summary of the key findings of 
Figure 2. Summary Mendelian randomization (MR) estimates derived from the main inverse-variance weighted (IVW), IVW excluding potentially pleiotropic 
single-nucleotide polymorphisms (SNPs), MR-Egger, MR pleiotropy residual sum and outlier (PRESSO), outlier-corrected MR-PRESSO, weighted median and 
weighted mode-based estimator methods for coronary artery disease (CAD), and myocardial infarction (MI). OR indicates odds ratio.
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the discussed observational studies in this area is available in 
Table XI in the online-only Data Supplement.
Strengths and Limitations
A consistent limitation of all of the discussed observational 
studies is that platelet count is affected by a range of con-
ditions, which may confound the analyses. For example, 
thrombocytopenia is associated with malignancy, liver di-
sease, autoimmune diseases, pregnancy, and infections.42 
Thrombocythemia is associated with iron deficiency, hemato-
logic malignancy, and chronic inflammation.43 Thus, the key 
advantage of the MR approach used in our study is that it over-
comes this potential source of bias by using genetic variants 
as instruments for platelet count.13,16,18 Furthermore, MR uses 
genetic variants that are allocated at conception as instruments 
for the exposure of interest and is therefore not affected by 
reverse causation as case-control studies might be.
We have taken a rigorous methodological approach in our 
MR analyses. The SNPs selected as instruments for the MR 
analysis were associated with platelet count at genome-wide 
significance, reducing the risk of using invalid instruments. 
Furthermore, the F statistics were above 10 for all SNPs, indi-
cating that the instruments were unlikely to suffer marked 
weak instrument bias.17 We incorporated a range of sensitivity 
analyses to explore potential bias because of genetic pleiotropy 
in our approach. For these, the effect estimates were generally 
similar to those from the main IVW-MR analyses, although 
wider CIs were observed reflecting the reduced statistical 
power associated with these approaches (Figures 2 and 3). Of 
particular note, platelet count is closely related to other platelet 
Figure 3. Summary MR estimates derived from the main inverse-variance weighted (IVW), IVW excluding potentially pleiotropic single-nucleotide polymor-
phisms (SNPs), Mendelian randomization (MR)-Egger, MR pleiotropy residual sum and outlier (PRESSO), outlier-corrected MR-PRESSO, weighted median 
and weighted mode-based estimator methods for ischemic stroke, cardioembolic stroke, large-artery atherosclerotic stroke, and small vessel stroke. OR 
indicates odds ratio.
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and more general hematologic traits, both at an observational 
and a genetic level,16 and it was therefore important that we 
made every effort to investigate whether our MR estimates 
were biased by pleiotropic variants. While approaches such as 
multivariable MR allow adjustments to be made for any genetic 
association of the instruments with traits through which pleiot-
ropy is likely to be exerted,44 this approach was not appropriate 
for our current work. Specifically, multivariable MR can be se-
verely biased in the case of overlapping traits, such as would be 
expected for platelet and hematologic characteristics.45
MR assumes a linear relationship between the exposure 
and outcome,11 in our case genetically determined platelet 
count and disease risk. For this reason, the results of our MR 
analysis should not be extrapolated to extremes of platelet 
count. Use of genome-wide association studies may also re-
sult in the Winner’s curse,15 which can result in overestimation 
of the SNP-exposure estimate taken from the same popula-
tion used to identify instruments, and bias of our consequent 
2-sample MR estimate toward the null. Of further note, by 
using genetic variants as a marker of platelet count, MR 
accounts for the lifetime effect of this exposure.11 The MR 
results for the association between genetically determined 
platelet count and CVD risk should, therefore, not be directly 
extrapolated to estimate the effect of any potential clinical in-
tervention targeting platelet count.
Conclusions
This study used MR to investigate the association between 
genetically determined platelet count and cardiovascular risk. 
We report an increased risk of ischemic stroke with higher ge-
netically determined platelet count. Stroke is the second larg-
est cause of death worldwide,1 therefore, understanding its 
associated risk factors is a clinical and public health priority. 
These findings may thus guide further work toward identify-
ing preventative strategies.
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Highlights
• Cardiovascular disease is the leading cause of death worldwide.
• This study used Mendelian randomization analysis to test for a causal association between genetically determined platelet count and coronary 
artery disease, myocardial infarction, ischemic stroke, and ischemic stroke subtype risk.
• Genetically determined platelet count was associated with a higher risk of ischemic stroke and its subtypes.
• This study highlights the importance of platelet count as a risk factor for ischemic stroke and may be used to inform further studies aiming to 
harness this mechanism for clinical benefit.
